血管紧张素受体-脑啡肽酶抑制剂改善左心室辅助装置患者的血压和心力衰竭控制。
Angiotensin Receptor-Neprilysin Inhibition Improves Blood Pressure and Heart Failure Control in Left Ventricular Assist Device Patients.
机构信息
From the Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Division of Cardiothoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
出版信息
ASAIO J. 2021 Dec 1;67(12):e207-e210. doi: 10.1097/MAT.0000000000001435.
Angiotensin receptor-neprilysin inhibitors (ARNIs) greatly benefit functional capacity and longevity in heart failure with reduced ejection fraction (HFrEF). Angiotensin receptor-neprilysin inhibitors remain underutilized and unstudied, however, in left ventricular assist device (LVAD) recipients, in spite of their underlying HFrEF. In this case series, we studied the feasibility and short-term efficacy of ARNI utilization in 21 LVAD patients. Angiotensin receptor-neprilysin inhibitor initiation was successful in most, resulting in significant consolidation of blood pressure (BP) medical management and marked improvements in both functional capacity and diuretic requirements. Angiotensin receptor-neprilysin inhibitors are safe, feasible, and within a short timeframe benefit BP and heart failure control in LVAD recipients.
血管紧张素受体-脑啡肽酶抑制剂（ARNI）可极大改善射血分数降低的心力衰竭（HFrEF）患者的功能能力和预期寿命。然而，尽管左心室辅助装置（LVAD）受者存在 HFrEF，但血管紧张素受体-脑啡肽酶抑制剂的使用率仍然较低，且研究较少。在本病例系列中，我们研究了 21 例 LVAD 患者使用 ARNI 的可行性和短期疗效。血管紧张素受体-脑啡肽酶抑制剂的起始应用在大多数患者中是成功的，导致血压（BP）管理的显著强化，并显著改善了功能能力和利尿剂需求。血管紧张素受体-脑啡肽酶抑制剂是安全、可行的，在短时间内可使 LVAD 受者的血压和心力衰竭得到控制。
Zotero 插件